ES2190115T3 - Derivados de acido hidroxamico y carboxilico con actividad inhibidora de mmp y tnf. - Google Patents

Derivados de acido hidroxamico y carboxilico con actividad inhibidora de mmp y tnf.

Info

Publication number
ES2190115T3
ES2190115T3 ES98952927T ES98952927T ES2190115T3 ES 2190115 T3 ES2190115 T3 ES 2190115T3 ES 98952927 T ES98952927 T ES 98952927T ES 98952927 T ES98952927 T ES 98952927T ES 2190115 T3 ES2190115 T3 ES 2190115T3
Authority
ES
Spain
Prior art keywords
alkyl
hydroxamic
mmp
tnf
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98952927T
Other languages
English (en)
Inventor
Andrew Douglas Baxter
David Alan Owen
John Gary Montana
Robert John Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Darwin Discovery Ltd
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9723906.5A external-priority patent/GB9723906D0/en
Priority claimed from GBGB9802618.0A external-priority patent/GB9802618D0/en
Priority claimed from GBGB9813933.0A external-priority patent/GB9813933D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of ES2190115T3 publication Critical patent/ES2190115T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

Compuesto para utilización terapéutica, representado por la **fórmula** en la que m es 0-2; X es S(O)1-2 Y es OH ó NHOH; R1 es H ó un grupo (sustituido opcionalmente por R7) seleccionado de entre alquil C1-6, alquenil C2-6, aril, alquil-aril C1-6, heteroaril, alquil-heteroaril C1-6, heterocicloalquil, alquil-heterocicloalquil C1-6, cicloalquil y alquil-cicloalquil C1-6, y R2 es H ó alquil C1-6; ó CR1R2 es un anillo de cicloalquil o heterocicloalquil opcionalmente sustituido por R7 o un grupo (opcionalmente sustituido por R7) seleccionado de entre alquil C1-6, aril, alquil-aril C1-6, heteroaril y alquil-heteroaril C1-6.
ES98952927T 1997-11-12 1998-11-12 Derivados de acido hidroxamico y carboxilico con actividad inhibidora de mmp y tnf. Expired - Lifetime ES2190115T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9723906.5A GB9723906D0 (en) 1997-11-12 1997-11-12 Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activiy
GBGB9802618.0A GB9802618D0 (en) 1998-02-06 1998-02-06 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
GBGB9813933.0A GB9813933D0 (en) 1998-06-26 1998-06-26 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity

Publications (1)

Publication Number Publication Date
ES2190115T3 true ES2190115T3 (es) 2003-07-16

Family

ID=27269088

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98952927T Expired - Lifetime ES2190115T3 (es) 1997-11-12 1998-11-12 Derivados de acido hidroxamico y carboxilico con actividad inhibidora de mmp y tnf.

Country Status (18)

Country Link
EP (1) EP1030836B1 (es)
JP (1) JP2001522832A (es)
KR (1) KR100609926B1 (es)
CN (1) CN1283183A (es)
AT (1) ATE231837T1 (es)
AU (1) AU748843B2 (es)
BR (1) BR9814147A (es)
CA (1) CA2308359A1 (es)
DE (1) DE69811111T2 (es)
DK (1) DK1030836T3 (es)
ES (1) ES2190115T3 (es)
HU (1) HUP0100152A3 (es)
IL (1) IL135921A (es)
NO (1) NO20002440L (es)
NZ (1) NZ504387A (es)
PL (1) PL340551A1 (es)
RU (1) RU2210567C2 (es)
WO (1) WO1999024399A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL131042A (en) * 1997-02-03 2004-07-25 Pfizer Prod Inc Derivatives of arylsulfonamic acid hydroxyamic acid and medicinal preparations containing them
JP2002523492A (ja) 1998-08-29 2002-07-30 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド タンパク質分解酵素阻害剤としてのヒドロキサム酸誘導体
JP2002530278A (ja) 1998-11-12 2002-09-17 ダーウィン・ディスカバリー・リミテッド Ｍｍｐおよびｔｎｆ阻害活性を有するヒドロキサムおよびカルボン酸誘導体
JP2002536373A (ja) * 1999-02-08 2002-10-29 ジー・ディー・サール・アンド・カンパニー スルファメトヒドロキサム酸メタロプロテアーゼ阻害剤
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
GB9929527D0 (en) * 1999-12-14 2000-02-09 Smithkline Beecham Plc Novel compounds
ES2208595T3 (es) 2000-05-15 2004-06-16 Darwin Discovery Limited Derivados del acido hidroxamico.
EP1292576A1 (en) 2000-05-15 2003-03-19 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US6469020B2 (en) 2000-05-15 2002-10-22 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives
AU2001290134A1 (en) 2000-09-29 2002-04-08 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
EP2292593A3 (en) * 2000-09-29 2011-05-25 TopoTarget UK Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
US20040147573A1 (en) * 2001-03-15 2004-07-29 Anders Eriksson Metalloproteinase inhibitors
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
GB0119396D0 (en) * 2001-08-09 2001-10-03 Celltech R&D Ltd Hydroxamic acid derivatives
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
AU2003229883B2 (en) 2002-04-03 2009-06-11 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
CA2483314A1 (en) 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
GB0216382D0 (en) * 2002-07-13 2002-08-21 Astrazeneca Ab Compounds
GB0216383D0 (en) * 2002-07-13 2002-08-21 Astrazeneca Ab Compounds
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
AU2004205372B2 (en) 2003-01-17 2011-02-24 Topotarget Uk Limited Hydroxamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
JP5539717B2 (ja) * 2006-07-14 2014-07-02 塩野義製薬株式会社 オキシム化合物およびその使用
US8563732B2 (en) 2007-05-31 2013-10-22 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
ES2408159T3 (es) 2008-06-11 2013-06-18 Shionogi & Co., Ltd. Compuestos de oxicarbamoilo y su utilización
KR20220164216A (ko) * 2021-06-04 2022-12-13 에스티팜 주식회사 신규한 에르고스텐올 유도체 및 이의 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1067965A (en) * 1965-01-22 1967-05-10 Beecham Group Ltd Penicillins, esters, amides and salts thereof

Also Published As

Publication number Publication date
CN1283183A (zh) 2001-02-07
CA2308359A1 (en) 1999-05-20
IL135921A (en) 2005-08-31
AU748843B2 (en) 2002-06-13
PL340551A1 (en) 2001-02-12
EP1030836B1 (en) 2003-01-29
ATE231837T1 (de) 2003-02-15
NO20002440D0 (no) 2000-05-11
AU1046999A (en) 1999-05-31
DE69811111T2 (de) 2003-07-24
IL135921A0 (en) 2001-05-20
NO20002440L (no) 2000-05-11
JP2001522832A (ja) 2001-11-20
BR9814147A (pt) 2000-10-03
DK1030836T3 (da) 2003-05-26
HUP0100152A2 (hu) 2002-02-28
EP1030836A1 (en) 2000-08-30
DE69811111D1 (de) 2003-03-06
NZ504387A (en) 2002-10-25
KR20010032042A (ko) 2001-04-16
WO1999024399A1 (en) 1999-05-20
HUP0100152A3 (en) 2002-07-29
KR100609926B1 (ko) 2006-08-04
RU2210567C2 (ru) 2003-08-20

Similar Documents

Publication Publication Date Title
ES2190115T3 (es) Derivados de acido hidroxamico y carboxilico con actividad inhibidora de mmp y tnf.
DK0659174T3 (da) Derivater af valproinsyre og 2-valproensyreamider samt deres anvendelse som antikonvulsive midler
RU94021350A (ru) Соединения, содержащие конденсированное бициклическое ядро, промежуточные соединения, способы их получения, фармацевтическая композиция
NZ218786A (en) 1,4 disubstituted piperidine derivatives and pharmaceutical compositions
DK162528C (da) 7-oxabicycloheptan-derivater samt laegemiddel indeholdende disse
ES2054826T3 (es) Peptidos con actividad inhibidora de colagenasa.
PT96916A (pt) Processo para a preparacao de composicoes farmaceuticas contendo um macrolido
RU93005334A (ru) Производные стероидов для лечения гипертрофии предстательной железы, способ их получения, использование, фармкомпозиция
DE3665711D1 (de) Novel guanidinomethylbenzoic acid derivatives
ATE122042T1 (de) Pyrazoloisoquinoline-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
DE3363593D1 (en) 2-nitro-ethene diamines, process for their preparation and their use as medicines
DE69509875D1 (de) Nipecotinsäurederivate als antithrombische verbindungen
NO942983L (no) Farmasöytiske sammensetninger
ATE149165T1 (de) Stickstoff enthaltende bizyklische derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
GR3017022T3 (en) Pyridone derivatives, process for their preparation, novel obtained intermediates, their use as medicines and pharmaceutical compositions containing them.
ZA951013B (en) Novel indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase
ES2186127T3 (es) Sintesis de derivados de nucleosidos aciclicos.
EA200100806A1 (ru) Производные алкинилсодержащих гидроксамовых кислот, способы их получения и применение указанных веществ в качестве ингибиторов матриксной металлопротеиназы (ммр) и фно-альфа-конвертирующего фермента (tace)
DE3882956T2 (de) Gegen die zerebrale Insuffizienz wirksame Verbindungen.
ES8609316A1 (es) Un procedimiento para la produccion de nuevos derivados de ergolina
ECSP951430A (es) Derivados de acidos hidroxamico con sustitucion triciclica